Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029
세계의 경구 단백질 및 펩티드 시장 규모는 2024년 73억 8,000만 달러로 추정되고, 2029년까지 203억 6,000만 달러에 이를 것으로 예측되며, 2024년부터 2029년까지 예측 기간 동안 CAGR 22.5%로 성장이 예상됩니다.
시장의 성장은 당뇨병이나 중추신경계 질환 등 만성 질환의 치료에 대한 경구 펩티드 수요 증가, 혁신적인 경구 펩티드의 개발과 출시를 향한 주요 기업에 의한 연구 개발 투자 증가, 약물전달 기술의 지속적인 진보에 의해 크게 촉진되고 있습니다. 그러나 높은 개발 비용과 제형화 및 안정성 장애물은 시장 성장을 억제합니다.
| 조사 범위 |
| 조사 대상년도 |
2022-2029년 |
| 기준년 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
달러 |
| 부문 |
분자별, 약물 클래스별, 치료 영역별, 제형별, 최종 사용자별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
"분자별로는 세마글루티드 분자 부문이 2023년에 가장 큰 점유율을 차지했습니다."
세마글루티드는 글루카곤 유사 펩티드-1(GLP-1)의 아날로그로, 혈당치와 식욕의 조절에 관여하는 호르몬입니다. 2형 당뇨병과 비만증의 치료에 이용됩니다. 세마글루티드는 상승한 혈당에 반응하여 인슐린 분비를 촉진하고 글루카곤 방출(혈당 상승)을 억제하고 식후의 포만감을 촉진함으로써 식이 섭취량을 감소시키는 작용을 가지고 있습니다. 경구세마글루티드(리베르수스)는 제2형 당뇨병 치료제로서 미국 FDA에 승인된 첫 경구글루카곤 유사 펩타이드1(GLP-1) 수용체 작동제입니다. GLP-1 수용체 작용제는 2형 당뇨병 치료제로 널리 사용되고 있으며 권장됩니다.
“미국이 2024년부터 2029년 예측 기간에 경구 단백질 및 펩티드 시장을 계속 독점할 전망입니다.”
미국은 세계 최대의 바이오 의약품 시장이며, 바이오 의약품 연구 및 투자의 리더입니다. 감염증으로 고통받는 환자의 증가나, 바이오 의약품의 중요성의 고조, 의료 부문에 있어서의 안전하고 고품질의 제품에의 요구에 의해, 정부 기관, 제약 기업, 생명 공학 회사에 의한 바이오 의학 연구에 대한 투자 및 자금 조달이 확대되고 있습니다. 신기술과 대체요법의 조기 채용은 이 지역에서 대부분의 경구 단백질 및 펩티드의 이용가능성에 힘입어 시장의 성장을 더욱 뒷받침하고 있습니다. 또, 이지역에 있어서의 복수의 시장 참가 기업의 확립된 강한 존재도 시장 성장을 지원하는 주요 요인이 되고 있습니다. 이러한 주요 기업에는 Nordisk A/S(덴마크), AbbVie, Inc.(미국), Pfizer Inc.(미국)가 포함됩니다.
이 보고서는 세계의 경구 단백질 및 펩티드 시장에 대한 조사 분석을 통해 주요 촉진요인 및 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
- 경구 단백질 및 펩티드 시장 개요
- 북미의 경구 단백질 및 펩티드 시장 점유율 : 제형별 및 국가별(2023년)
- 경구 단백질 및 펩티드 시장 점유율 : 치료 영역별(2023년)
- 경구 단백질 및 펩티드 시장 점유율 : 최종 사용자별(2024년, 2029년)
- 경구 단백질 및 펩티드 시장 : 지리적 성장 기회
제5장 시장 개요
- 서문
- 시장 역학
- 생태계 분석
- 원재료 벤더의 역할
- 제품 제공업체의 역할
- 최종 사용자의 역할
- 규제 당국의 역할
- 밸류체인 분석
- 공급망 분석
- Porter's Five Forces 분석
- 주요 이해관계자와 구매 기준
- 가격 분석
- 경구 단백질 및 펩티드 제품의 가격 분석
- 주된 경구 단백질 및 펩티드의 가격 분석 : 국가별 및 지역별
- 규제 상황
- 규제 시나리오
- 규제기관, 정부기관, 기타 조직
- 고객의 비즈니스에 영향을 미치는 동향 및 혼란
- 기술 분석
- 파이프라인 분석
- 특허 분석
- 주요 컨퍼런스 및 이벤트(2024-2025년)
- 투자와 자금조달 시나리오
- 경구 단백질 및 펩티드 시장에 대한 AI의 영향
제6장 경구 단백질 및 펩티드 시장 : 분자별
- 서문
- 세마글루티드
- 칼시토닌
- 리나크로티드
- 트로피네티드
- 보크로스포린
- 프리카나티드
- 기타 분자
제7장 경구 단백질 및 펩티드 시장 : 약제 클래스별
- 서문
- 글루카곤 유사 펩티드-1 수용체 작용제
- 칼시토닌 유전자 관련 펩티드 수용체 길항제
- 구아닐산 시클라아제 C 작용제
- 글리신-프롤린-글루탐산
- 칼시뉴린 억제 면역억제제
- 기타 약물 클래스
제8장 경구 단백질 및 펩티드 시장 : 치료 영역별
- 서문
- 당뇨병
- 중추 신경계 장애
- 소화기 내과
- 유전성 질환
- 신장
- 비만 및 과체중
- 기타 치료 영역
제9장 경구 단백질 및 펩티드 시장 : 제형별
제10장 경구 단백질 및 펩티드 시장 : 최종 사용자별
- 서문
- 재택 케어 환경
- 장기 케어 시설
- 병원 및 전문 클리닉
제11장 경구 단백질 및 펩티드 시장 : 지역별
- 서문
- 북미
- 유럽
- 유럽의 거시 경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시 경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시 경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 중동의 거시 경제 전망
- GCC 국가
- 기타 중동
- 아프리카
제12장 경쟁 구도
- 개요
- 주요 전략 및 유력 기업
- 수익분배분석
- 시장 점유율 분석
- 기업의 평가 매트릭스 : 주요 기업(2023년)
- 기업의 평가 매트릭스 : 파이프라인에 제품을 가진 기업(2023년)
- 기업의 평가 매트릭스 : 스타트업 및 중소기업(2023년)
- 평가 및 재무 지표
- 브랜드 및 제품 비교
- 경쟁 시나리오
제13장 기업 프로파일
- 서문
- 주요 기업
- NOVO NORDISK A/S
- ABBVIE INC.
- PFIZER INC.
- BAUSCH HEALTH COMPANIES INC.
- CHIESI FARMACEUTICI SPA
- ACADIA PHARMACEUTICALS INC.
- AURINIA PHARMACEUTICALS INC.
- MERCK & CO., INC.
- JOHNSON & JOHNSON SERVICES, INC.
- SWK HOLDINGS
- R-PHARM JSC
- ENTERA BIO LTD.
- PROXIMA CONCEPTS
- 기타 기업
- ASTRAZENECA PLC
- REGOR THERAPEUTICS GROUP
- TERNS PHARMACEUTICALS, INC.
- STRUCTURE THERAPEUTICS
- VIKING THERAPEUTICS
- PROTAGONIST THERAPEUTICS INC.
- RANI THERAPEUTICS
- CARMOT THERAPEUTICS, INC.
- ZEALAND PHARMA
- SCIWIND BIOSCIENCES CO., LTD.
- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
제14장 부록
AJY
The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029. The growth of the oral proteins and peptides market has been significantly driven by its increasing demand of oral peptides for the treatment of chronic diseases such as diabetes and CNS disorders, increasing R&D investment by key players for the development and launch of innovative oral peptides and continuous advancements in drug delivery technologies. However, high development cost and the hurdles in formulation and stability are restraining market growth.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Molecule, Drug Class, Therapeutic Area, Formulation, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The semaglutide molecule segment accounted for the largest share by molecule in 2023."
In 2023, the semaglutide segment accounted for the largest share by molecule in the global oral proteins and peptides market. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes and obesity. Semaglutide works by enhancing insulin secretion in response to elevated blood glucose, reducing glucagon release (which raises blood sugar), and promoting a feeling of fullness after eating, which can help reduce food intake. Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes.
"The US has continued to dominate the oral proteins and peptides market during the forecast period of 2024-2029."
The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of oral proteins and peptides in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), Pfizer Inc. (US)
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of key Companies Profiled in the Report:
Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)
Research Coverage:
This research report categorizes the oral proteins and peptides market by molecule (Trofinetide, Semaglutide, Linaclotide, Voclosporin, Plecanatide, Calcitonin, and Others), by Drug Class (Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others), by Therapeutic Area (Genetic Disorder, Diabetes, Nephrology, Gastroenterology, CNS Disorders, Obesity & Overweight, and Others) by Formulation (Tablet, Capsules, and Oral Solution), by End User (Home Care Settings, Long-Term Care Facilities, Hospitals & Specialty Clinics) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 INSIGHTS FROM PRIMARIES
- 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
- 2.3 MARKET GROWTH FORECAST
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
- 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023)
- 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023
- 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029
- 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increasing burden of chronic diseases
- 5.2.1.2 Advancements in drug delivery technologies
- 5.2.1.3 Higher patient compliance and preference for oral route
- 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of drug development
- 5.2.2.2 Contraindication of oral proteins & peptides
- 5.2.2.3 Stringent regulatory approval process
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
- 5.2.3.2 Growing demand for personalized medicine
- 5.2.4 CHALLENGES
- 5.2.4.1 Hurdles in formulation and stability
- 5.2.4.2 Availability of alternative therapies
- 5.3 ECOSYSTEM ANALYSIS
- 5.3.1 ROLE OF RAW MATERIAL VENDORS
- 5.3.2 ROLE OF PRODUCT PROVIDERS
- 5.3.3 ROLE OF END USERS
- 5.3.4 ROLE OF REGULATORY AUTHORITIES
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 PORTER'S FIVE FORCES ANALYSIS
- 5.6.1 THREAT OF NEW ENTRANTS
- 5.6.2 THREAT OF SUBSTITUTES
- 5.6.3 BARGAINING POWER OF SUPPLIERS
- 5.6.4 BARGAINING POWER OF BUYERS
- 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.7.1 KEY STAKEHOLDERS
- 5.7.2 BUYING CRITERIA
- 5.8 PRICING ANALYSIS
- 5.8.1 PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS
- 5.8.2 PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION
- 5.9 REGULATORY LANDSCAPE
- 5.9.1 REGULATORY SCENARIO
- 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
- 5.11.1.1 Transient permeation enhancer
- 5.11.1.2 Gastrointestinal permeation enhancement technology
- 5.11.1.3 Oral sCT (OSTORA) technology
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
- 5.11.2.1 Peptelligence
- 5.11.2.2 ThioMatrix
- 5.11.2.3 Transferrin-based recombinant fusion protein
- 5.11.3 ADJACENT TECHNOLOGIES
- 5.11.3.1 Oramed and Orasome
- 5.11.3.2 Q-sphera
- 5.11.3.3 Nanoinclusion
- 5.11.3.4 Oleotec and Soctec
- 5.12 PIPELINE ANALYSIS
- 5.13 PATENT ANALYSIS
- 5.13.1 METHODOLOGY
- 5.13.2 INNOVATION AND PATENT APPLICATIONS
- 5.13.3 TOP APPLICANTS
- 5.14 KEY CONFERENCES & EVENTS, 2024-2025
- 5.15 INVESTMENT & FUNDING SCENARIO
- 5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE
- 6.1 INTRODUCTION
- 6.2 SEMAGLUTIDE
- 6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
- 6.3 CALCITONIN
- 6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
- 6.4 LINACLOTIDE
- 6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
- 6.5 TROFINETIDE
- 6.5.1 FDA APPROVAL TO SUPPORT GROWTH
- 6.6 VOCLOSPORIN
- 6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
- 6.7 PLECANATIDE
- 6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
- 6.8 OTHER MOLECULES
7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS
- 7.1 INTRODUCTION
- 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
- 7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
- 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
- 7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
- 7.4 GUANYLATE CYCLASE-C AGONISTS
- 7.4.1 RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET
- 7.5 GLYCINE-PROLINE-GLUTAMATE
- 7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
- 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
- 7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
- 7.7 OTHER DRUG CLASSES
8 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA
- 8.1 INTRODUCTION
- 8.2 DIABETES
- 8.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
- 8.3 CNS DISORDERS
- 8.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
- 8.4 GASTROENTEROLOGY
- 8.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
- 8.5 GENETIC DISORDERS
- 8.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
- 8.6 NEPHROLOGY
- 8.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
- 8.7 OBESITY & OVERWEIGHT
- 8.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
- 8.8 OTHER THERAPEUTIC AREAS
9 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION
- 9.1 INTRODUCTION
- 9.2 TABLETS
- 9.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
- 9.3 CAPSULES
- 9.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
- 9.4 ORAL SOLUTIONS
- 9.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH
10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 HOME CARE SETTINGS
- 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
- 10.3 LONG-TERM CARE FACILITIES
- 10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
- 10.4 HOSPITALS & SPECIALTY CLINICS
- 10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 11.2.2 US
- 11.2.2.1 US to hold large share of North American and global markets
- 11.2.3 CANADA
- 11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
- 11.3 EUROPE
- 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 11.3.2 GERMANY
- 11.3.2.1 Germany to hold largest share of European market
- 11.3.3 UK
- 11.3.3.1 Strong focus on advancement of life sciences to support market growth
- 11.3.4 FRANCE
- 11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
- 11.3.5 ITALY
- 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
- 11.3.6 SPAIN
- 11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
- 11.3.7 NETHERLANDS
- 11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
- 11.3.8 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 11.4.2 CHINA
- 11.4.2.1 Increasing R&D expenditure to drive market
- 11.4.3 JAPAN
- 11.4.3.1 Increasing prevalence of diabetes to drive market
- 11.4.4 INDIA
- 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
- 11.4.5 AUSTRALIA
- 11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
- 11.4.6 SOUTH KOREA
- 11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 11.5.2 BRAZIL
- 11.5.2.1 Brazil to hold largest market share in Latin America
- 11.5.3 MEXICO
- 11.5.3.1 Growing diabetes and obesity cases to support market growth
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
- 11.6.2 GCC COUNTRIES
- 11.6.2.1 Saudi Arabia
- 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
- 11.6.2.2 UAE
- 11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to propel market
- 11.6.2.3 Rest of GCC countries
- 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
- 11.7.2 AFRICA: MACROECONOMIC OUTLOOK
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 KEY STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES
- 12.3 REVENUE SHARE ANALYSIS
- 12.4 MARKET SHARE ANALYSIS
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
- 12.6.1 STARS
- 12.6.2 EMERGING LEADERS
- 12.6.3 PERVASIVE PLAYERS
- 12.6.4 PARTICIPANTS
- 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 12.6.5.1 Company Footprint
- 12.6.5.2 Molecule footprint
- 12.6.5.3 Formulation footprint
- 12.6.5.4 Therapeutic area footprint
- 12.6.5.5 Region footprint
- 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.7.1 PROGRESSIVE COMPANIES
- 12.7.2 RESPONSIVE COMPANIES
- 12.7.3 DYNAMIC COMPANIES
- 12.7.4 STARTING BLOCKS
- 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.7.5.1 Detailed list of key startups/SMEs
- 12.7.5.2 Competitive benchmarking of key startups/SMEs
- 12.8 VALUATION & FINANCIAL METRICS
- 12.8.1 FINANCIAL METRICS
- 12.8.2 COMPANY VALUATION
- 12.9 BRAND/PRODUCT COMPARISON
- 12.10 COMPETITIVE SCENARIO
- 12.10.1 PRODUCT APPROVALS
- 12.10.2 DEALS
- 12.10.3 EXPANSIONS
- 12.10.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
- 13.1 INTRODUCTION
- 13.2 KEY PLAYERS
- 13.2.1 NOVO NORDISK A/S
- 13.2.1.1 Business overview
- 13.2.1.2 Products offered
- 13.2.1.3 Recent developments
- 13.2.1.3.1 Product launches & approvals
- 13.2.1.3.2 Expansions
- 13.2.1.3.3 Other developments
- 13.2.1.4 MnM view
- 13.2.1.4.1 Right to win
- 13.2.1.4.2 Strategic choices
- 13.2.1.4.3 Weaknesses & competitive threats
- 13.2.2 ABBVIE INC.
- 13.2.2.1 Business overview
- 13.2.2.2 Products offered
- 13.2.2.3 Recent developments
- 13.2.2.3.1 Product approvals
- 13.2.2.4 MnM view
- 13.2.2.4.1 Right to win
- 13.2.2.4.2 Strategic choices
- 13.2.2.4.3 Weaknesses & competitive threats
- 13.2.3 PFIZER INC.
- 13.2.3.1 Business overview
- 13.2.3.2 Product pipeline
- 13.2.3.3 Recent developments
- 13.2.3.3.1 Product approvals
- 13.2.3.3.2 Deals
- 13.2.3.3.3 Other developments
- 13.2.3.4 MnM view
- 13.2.3.4.1 Right to win
- 13.2.3.4.2 Strategic choices
- 13.2.3.4.3 Weaknesses & competitive threats
- 13.2.4 BAUSCH HEALTH COMPANIES INC.
- 13.2.4.1 Business overview
- 13.2.4.2 Products offered
- 13.2.4.3 Recent developments
- 13.2.4.3.1 Product approvals
- 13.2.5 CHIESI FARMACEUTICI S.P.A.
- 13.2.5.1 Business overview
- 13.2.5.2 Products offered
- 13.2.5.3 Recent developments
- 13.2.6 ACADIA PHARMACEUTICALS INC.
- 13.2.6.1 Business overview
- 13.2.6.2 Products offered
- 13.2.6.3 Recent developments
- 13.2.6.3.1 Product approvals
- 13.2.7 AURINIA PHARMACEUTICALS INC.
- 13.2.7.1 Business overview
- 13.2.7.2 Products offered
- 13.2.7.3 Recent developments
- 13.2.7.3.1 Product approvals
- 13.2.8 MERCK & CO., INC.
- 13.2.8.1 Business overview
- 13.2.8.2 Product pipeline
- 13.2.8.3 Recent developments
- 13.2.8.3.1 Other developments
- 13.2.9 JOHNSON & JOHNSON SERVICES, INC.
- 13.2.9.1 Business overview
- 13.2.9.2 Product pipeline
- 13.2.9.3 Recent developments
- 13.2.9.3.1 Other developments
- 13.2.10 SWK HOLDINGS
- 13.2.10.1 Business overview
- 13.2.10.2 Product pipeline
- 13.2.10.3 Recent developments
- 13.2.10.3.1 Other developments
- 13.2.11 R-PHARM JSC
- 13.2.11.1 Business overview
- 13.2.11.2 Products in pipeline
- 13.2.12 ENTERA BIO LTD.
- 13.2.12.1 Business overview
- 13.2.12.2 Product pipeline
- 13.2.12.3 Recent developments
- 13.2.12.3.1 Deals
- 13.2.12.3.2 Other developments
- 13.2.13 PROXIMA CONCEPTS
- 13.2.13.1 Business overview
- 13.2.13.2 Products in pipeline
- 13.3 OTHER PLAYERS
- 13.3.1 ASTRAZENECA PLC
- 13.3.2 REGOR THERAPEUTICS GROUP
- 13.3.3 TERNS PHARMACEUTICALS, INC.
- 13.3.4 STRUCTURE THERAPEUTICS
- 13.3.5 VIKING THERAPEUTICS
- 13.3.6 PROTAGONIST THERAPEUTICS INC.
- 13.3.7 RANI THERAPEUTICS
- 13.3.8 CARMOT THERAPEUTICS, INC.
- 13.3.9 ZEALAND PHARMA
- 13.3.10 SCIWIND BIOSCIENCES CO., LTD.
- 13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
